Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data
根据 PAM50 亚型,HER2 阳性乳腺癌患者接受新辅助帕妥珠单抗/曲妥珠单抗治疗与接受曲妥珠单抗联合标准化疗治疗的病理完全缓解率存在差异:一项基于真实世界数据的分析
期刊:Frontiers in Oncology
影响因子:3.3
doi:10.3389/fonc.2019.01178
Díaz-Redondo, Tamara; Lavado-Valenzuela, Rocio; Jimenez, Begoña; Pascual, Tomas; Gálvez, Fernando; Falcón, Alejandro; Alamo, Maria Del Carmen; Morales, Cristina; Amerigo, Marta; Pascual, Javier; Sanchez-Muñoz, Alfonso; González-Guerrero, Macarena; Vicioso, Luis; Laborda, Aurora; Ortega, Maria Victoria; Perez, Lidia; Fernandez-Martinez, Aranzazu; Chic, Nuria; Jerez, Jose Manuel; Alvarez, Martina; Prat, Aleix; Ribelles, Nuria; Alba, Emilio